E2 ModerateModerate confidencePEM not requiredObservationalPeer-reviewedMachine draft
Chronic fatigue syndrome and arthralgia following parvovirus B19 infection.
Kerr, Jonathan R, Bracewell, Janice, Laing, Ian et al. · The Journal of rheumatology · 2002
Quick Summary
This study looked at whether parvovirus B19 infection (a common virus that causes rash and joint pain) can lead to chronic fatigue syndrome (CFS). Researchers followed 51 patients with acute B19 infection and found that some developed lasting joint pain and fatigue months later. Five patients met the diagnostic criteria for CFS after B19 infection, but the study found it very difficult to prove that B19 was the cause without clear evidence of infection at the time fatigue started.
Why It Matters
This study provides evidence that parvovirus B19 infection may trigger ME/CFS in some patients, potentially identifying a viral trigger for disease onset. Understanding post-viral ME/CFS mechanisms and the challenges in proving causation is important for developing better diagnostic criteria and investigating whether specific viral infections contribute to ME/CFS pathogenesis.
Observed Findings
- Acute B19 arthralgia occurred in 31/51 (61%) of acutely infected patients and was significantly associated with female sex and age >20 years.
- At follow-up (mean 22.5 months), 18 patients had persistent symptoms: arthralgia alone (n=5), arthralgia with fatigue (n=6), fatigue alone (n=7), and other manifestations (n=3).
- Chronic B19 arthralgia was associated with persistent B19 viremia (p=0.029) and positive ANA at acute infection (p=0.0043).
- Five patients fulfilled CDC criteria for chronic fatigue syndrome, including one who was seronegative for anti-B19 IgG at follow-up.
- Comparison of B19 follow-up group with controls showed significantly increased prevalence of arthralgia (p=0.0002) and fatigue (p<0.0001).
Inferred Conclusions
- CFS may follow acute parvovirus B19 infection in a subset of patients.
- No characteristic pattern of B19 markers or autoantibodies distinguishes B19-associated CFS cases, making serological confirmation at fatigue onset critical for attribution.
- Chronic symptoms following B19 infection (arthralgia and fatigue) appear to be associated with persistent immune activation (viremia, ANA positivity) rather than acute infection alone.
- Recovery of B19-specific antibodies at follow-up is not universal in post-B19 CFS, complicating retrospective diagnosis.
Remaining Questions
What This Study Does Not Prove
This study does not establish a direct causal mechanism linking B19 to CFS—it shows temporal association but not causation. The small number of CFS cases (n=5) and the absence of specific B19 marker patterns in CFS patients means B19 cannot be considered a reliable diagnostic marker or universal cause of ME/CFS. The study also does not characterize the full clinical course or outcomes of post-B19 CFS.
Tags
Symptom:PainFatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
Metadata
- PMID
- 11911112
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →